These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 2179637

  • 1. Chronic myelogenous leukemia--the unfolding saga.
    Goldman JM, Grosveld G, Baltimore D, Gale RP.
    Leukemia; 1990 Mar; 4(3):163-7. PubMed ID: 2179637
    [No Abstract] [Full Text] [Related]

  • 2. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J, Serrano J, Jiménez A, Castillejo JA, Reina ML, González MG, Rodríguez MC, García I, Sánchez J, Maldonado J, Torres A.
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [Abstract] [Full Text] [Related]

  • 3. The biology of chronic myeloid leukemia.
    Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
    N Engl J Med; 1999 Jul 15; 341(3):164-72. PubMed ID: 10403855
    [No Abstract] [Full Text] [Related]

  • 4. [Chronic myeloid leukemia: progress and prospects].
    Baccarani M, Russo D, Fanin R.
    Haematologica; 1991 Jun 15; 76 Suppl 3():40-5. PubMed ID: 1752539
    [No Abstract] [Full Text] [Related]

  • 5. Genetic events in CML: from translocation to transplantation.
    Daley GQ.
    Bone Marrow Transplant; 1994 Jun 15; 14 Suppl 3():S5-9. PubMed ID: 7697009
    [No Abstract] [Full Text] [Related]

  • 6. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
    Kohler S, Galili N, Sklar JL, Donlon TA, Blume KG, Cleary ML.
    Leukemia; 1990 Aug 15; 4(8):541-7. PubMed ID: 2201832
    [Abstract] [Full Text] [Related]

  • 7. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
    Fernandes RS, Gorman AM, McGahon A, Lawlor M, McCann S, Cotter TG.
    Leukemia; 1996 Jun 15; 10 Suppl 2():s17-21. PubMed ID: 8649049
    [Abstract] [Full Text] [Related]

  • 8. [Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up].
    Hochhaus A, Hehlmann R.
    Internist (Berl); 1996 Oct 15; 37(10):1013-21. PubMed ID: 9019445
    [No Abstract] [Full Text] [Related]

  • 9. The molecular pathogenesis of the Philadelphia-positive leukemias: implications for diagnosis and therapy.
    Van Etten RA.
    Cancer Treat Res; 1993 Oct 15; 64():295-325. PubMed ID: 8095796
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
    Gewirtz AM.
    Bone Marrow Transplant; 1994 Oct 15; 14 Suppl 3():S57-61. PubMed ID: 7697011
    [No Abstract] [Full Text] [Related]

  • 11. Karyotype and BCR studies after bone marrow transplantation for chronic myeloid leukaemia.
    Ruutu T, Peltomäki P, Volin L, Lindlöf M, Knuutila S.
    Bone Marrow Transplant; 1991 Oct 15; 7 Suppl 2():20. PubMed ID: 1878697
    [No Abstract] [Full Text] [Related]

  • 12. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
    Goldman JM, Melo JV.
    N Engl J Med; 2003 Oct 09; 349(15):1451-64. PubMed ID: 14534339
    [No Abstract] [Full Text] [Related]

  • 13. Chronic myelogenous leukemia: from pathogenesis to therapy.
    Verfaillie CM.
    J Hematother; 1999 Feb 09; 8(1):3-13. PubMed ID: 10192297
    [No Abstract] [Full Text] [Related]

  • 14. Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase.
    Silver RT.
    Hematol Oncol Clin North Am; 1990 Apr 09; 4(2):319-35. PubMed ID: 2182594
    [Abstract] [Full Text] [Related]

  • 15. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Apr 09; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

  • 16. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 09; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 17. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P, Calabretta B.
    Haematologica; 1995 Aug 09; 80(4):295-9. PubMed ID: 7590496
    [No Abstract] [Full Text] [Related]

  • 18. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 19. Significance of detection of BCR/ABL transcript after allogeneic and autologous transplant.
    Saglio G, Guerrasio A, Gottardi E, Parziale A, Martinelli G, Zaccaria A, Frassoni F.
    Bone Marrow Transplant; 1994 Dec 14; 14 Suppl 3():S62-7. PubMed ID: 7697012
    [No Abstract] [Full Text] [Related]

  • 20. An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
    Polák J, Koza V, Cetkovský P, Haskovec C.
    Bone Marrow Transplant; 2000 May 14; 25(10):1109-10. PubMed ID: 10828875
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.